Class: Antineoplastic Agents
VA Class: AN900
Chemical Name: Immunoglobulin G 1 (human-mouse monoclonal rhuMAb-VEGF γ-chain anti-human vascular endothelial growth factor), disulfide with human-mouse monoclonal rhuMAb-VEGF light chain, dimer
Molecular Formula: C6638H10160N1720O2108S44
CAS Number: 216974-75-3
Medically reviewed on Jul 2, 2018
- GI Perforations
- Surgery and Wound Healing Complications
Increased incidence of surgical and wound healing complications; may be serious and fatal.1 Discontinue bevacizumab permanently if wound dehiscence and wound healing complications requiring medical intervention occur.1 (See Surgery and Wound Healing Complications under Cautions.)
Appropriate interval between discontinuance of bevacizumab and subsequent elective surgery required to decrease risk of wound healing complications not established.1 However, manufacturer recommends discontinuing therapy ≥28 days prior to elective surgery.1
Do not initiate therapy until ≥28 days following major surgery and after surgical incision has fully healed.1
Uses for Bevacizumab
Used in combination with IV fluorouracil-based chemotherapy for the first-line treatment of metastatic cancer of the colon or rectum.1 2 3 4 9 Analysis of pooled data suggests that use of bevacizumab in combination with fluorouracil and leucovorin is associated with prolonged survival.20
Used in combination with IV fluorouracil-based chemotherapy for the second-line treatment of previously treated metastatic cancer of the colon or rectum.1 Interim analysis of data from one study indicated bevacizumab monotherapy† was associated with decreased survival compared with combination regimen consisting of fluorouracil, leucovorin, and oxaliplatin.1
Investigated for use in combination with fluorouracil, leucovorin, and oxaliplatin (modified FOLFOX6)† as adjuvant therapy following surgery for early-stage (i.e., stage II or III)† colon cancer.28 Data from a randomized study demonstrated no improvement in disease-free survival; therefore, such use not recommended.53
Non-small Cell Lung Cancer
Used in combination with carboplatin and paclitaxel for first-line treatment of unresectable, locally advanced, recurrent or metastatic nonsquamous NSCLC.1 10 Data from a randomized study suggest that use of bevacizumab in combination with carboplatin and paclitaxel is associated with prolonged survival; benefit less certain in women, patients ≥65 years of age, and those with ≥5% weight loss.1 11
Investigated for use in combination with cisplatin and gemcitabine† for first-line treatment of locally advanced, metastatic, or recurrent nonsquamous NSCLC.1 Data from a randomized study suggest that such use is associated with prolonged progression-free survival but not prolonged overall survival.1
Used as a single agent for treatment of glioblastoma in patients whose disease has progressed following radiation therapy and chemotherapy (i.e., temozolomide).1 Efficacy is based on increased objective response rate; currently, no data available that demonstrate prolonged overall survival or amelioration of disease-related symptoms.1 47 48
Renal Cell Carcinoma
Previously labeled for use in combination with paclitaxel for first-line treatment of metastatic HER2-negative breast cancer†.44 However, FDA concluded that such use has not been shown in postmarketing studies to prolong overall survival or provide sufficient clinical benefit (e.g., prolongation of progression-free survival, amelioration of disease-related symptoms, improvement in quality of life) to outweigh the risk of severe, potentially fatal, adverse effects (e.g., MI, CHF, severe hypertension, bleeding or hemorrhage, perforation and fistula/abscess formation,44 wound healing complications).65 66 68 Therefore, on November 18, 2011, FDA revoked approval of bevacizumab for this use;68 Health Canada, but not the European Medicines Agency (EMA), took similar action.65 69 The United Kingdom’s Institute for Health and Clinical Excellence (NICE) reached similar conclusions about the lack of evidence of clinical benefit and has not supported this use.65 70 The AHFS Oncology Expert Committee concluded that use of bevacizumab in combination with paclitaxel for first-line treatment of metastatic breast cancer currently is not fully established because of equivocal evidence.77
Patients currently receiving bevacizumab for breast cancer should consult their clinician about whether to continue bevacizumab therapy or consider other treatment options.67 Clinicians should use clinical judgment in deciding whether patients should continue receiving bevacizumab in combination with paclitaxel, receive paclitaxel monotherapy, or consider other treatment options.67
AHFS OncologyExpert Committee also concluded that use of bevacizumab in combination with chemotherapy (e.g., taxanes, capecitabine, gemcitabine, vinorelbine)14 75 for the treatment of metastatic breast cancer previously treated with cytotoxic chemotherapy† currently is not fully established because of equivocal evidence.78
Investigated for use in treatment of ovarian cancer†.26 Data from randomized studies suggest that use of bevacizumab in combination with carboplatin and paclitaxel is associated with prolonged progression-free survival, but not prolonged overall survival, and an increased risk of hypertension and GI perforation.71 72 Effects on overall survival not fully elucidated (i.e., no difference in overall survival reported in one study, final overall survival data not yet available for another study).71 72
Has been used by intravitreal injection† in treatment of neovascular age-related macular degeneration†.34 41 85 86 87 88 89 Appears to have similar efficacy as ranibizumab in improving visual acuity; however, conflicting data reported regarding relative risk of serious systemic adverse effects.41 87 88 Consider patient-specific factors, which may vary the level of risk, prior to intravitreal use.88 (See Ocular Effects under Cautions.)
Bevacizumab Dosage and Administration
Use alone or in combination with other chemotherapeutic agents.1 (See Dosage under Dosage and Administration.)
Do not initiate therapy until ≥28 days following major surgery and after surgical incision has fully healed.1 (See Surgery and Wound Healing Complications under Cautions.)
Discontinue therapy ≥28 days prior to elective surgery; do not resume until surgical incision has fully healed.1 (See Surgery and Wound Healing Complications under Cautions.)
For solution and drug compatibility information, see Compatibility under Stability.
Do not shake vial prior to dilution.1
Rate of Administration
Administer initial dose over 90 minutes.1 (See Infusion Reactions under Cautions.)
If well tolerated, administer second dose over 60 minutes.1
If second dose is well tolerated, administer subsequent doses over 30 minutes.1
Has been administered safely over shorter infusion times (0.5 mg/kg per minute).43
Consult respective manufacturers or published protocols for dosage, method of administration, and administration sequence of drugs in combination regimens.3
First-line Treatment of Metastatic Colorectal CancerIV
5 mg/kg every 2 weeks; continue until disease progression or unacceptable toxicity occurs.1
Use in combination with IV fluorouracil-based chemotherapy.1 In clinical studies, bevacizumab was used in combination with the IFL regimen (irinotecan 125 mg/m2, fluorouracil 500 mg/m2, and leucovorin 20 mg/m2, administered by IV injection once weekly for 4 out of every 6 weeks)1 4 or the 5-FU/LV regimen (leucovorin 500 mg/m2 by IV infusion over 2 hours, then fluorouracil 500 mg/m2 by slow IV injection [1 hour after initiation of leucovorin] given once weekly for the first 6 weeks out of every 8-week cycle).1 2 3
Second-line Treatment of Metastatic Colorectal CancerIV
10 mg/kg every 2 weeks; continue until disease progression or unacceptable toxicity occurs.1
Use in combination with IV fluorouracil-based chemotherapy.1 In clinical studies, bevacizumab was administered on day 1 of the treatment cycle prior to the FOLFOX4 regimen (oxaliplatin 85 mg/m2 and leucovorin 200 mg/m2 concurrently IV, then fluorouracil 400 mg/m2 by direct IV injection, followed by fluorouracil 600 mg/m2 by continuous IV infusion on day 1; and leucovorin 200 mg/m2 IV, then fluorouracil 400 mg/m2 by direct IV injection, followed by fluorouracil 600 mg/m2 by continuous IV infusion on day 2; treatment cycles repeated every 2 weeks).1
Non-small Cell Lung Cancer
Use in combination with IV paclitaxel and carboplatin (PC regimen).1 f In clinical studies, bevacizumab was administered 1 hour after the PC regimen (paclitaxel 200 mg/m2 by IV infusion over 3 hours, then carboplatin [at dose required to obtain AUC of 6 mg/mL per minute] by IV infusion over 15–30 minutes beginning 60 minutes after completion of paclitaxel; treatment cycles repeated every 3 weeks).1 11 d e f In these studies, patients received up to 6 cycles of bevacizumab in combination with the PC regimen, after which bevacizumab monotherapy (15 mg/kg every 3 weeks) was continued until disease progression or unacceptable toxicity occurred.1 11 d e f A median of 7 treatment cycles (including cycles of bevacizumab monotherapy) was administered.11
10 mg/kg every 2 weeks; continue until disease progression or unacceptable toxicity occurs.1
Renal Cell Carcinoma
10 mg/kg every 2 weeks; continue until disease progression or unacceptable toxicity occurs.1
Use in combination with interferon alfa (9 million units sub-Q 3 times weekly).1
First-line Treatment of Metastatic Breast Cancer†IV
10 mg/kg every 2 weeks; has been used in combination with IV paclitaxel (90 mg/m2 IV once weekly for 3 out of 4 weeks).64 However, this regimen has not been shown to prolong overall survival or provide sufficient clinical benefit to outweigh the risk of severe, potentially fatal, adverse effects.65 (See Breast Cancer under Uses.)
Dosage Modification for Toxicity
Discontinue therapy permanently if GI perforation (i.e., GI perforation, fistula formation in GI tract, intra-abdominal abscess), non-GI fistula formation involving an internal organ, wound dehiscence and wound healing complications requiring medical intervention, severe hemorrhage requiring medical intervention, severe arterial thromboembolic event, nephrotic syndrome, hypertensive crisis, or hypertensive encephalopathy occurs.1 7
Discontinue therapy if reversible posterior leukoencephalopathy syndrome (RPLS) occurs.1 31 32 (See Reversible Posterior Leukoencephalopathy Syndrome [RPLS] under Cautions.) Risk of reinitiating therapy in patients previously experiencing RPLS not known.1 32
Discontinue therapy temporarily in patients with evidence of moderate to severe proteinuria pending further evaluation, in patients with severe hypertension not controlled by medical management, or in patients with severe infusion reactions.1 (See Cautions.)
No dosage adjustment required in geriatric patients.1
Cautions for Bevacizumab
Consider the usual cautions, precautions, and contraindications of any other antineoplastic agents included in the therapeutic regimen.3
Severe, sometimes fatal, GI perforation reported; generally manifested as abdominal pain, nausea, vomiting, constipation, and fever.1 Usually occurs within the first 50 days following initiation of bevacizumab.1
If GI perforation (GI perforation, fistula formation in GI tract, and/or intra-abdominal abscess) occurs, discontinue bevacizumab permanently.1
Surgery and Wound Healing Complications
Wound healing and bleeding complications (including wound dehiscence), sometimes fatal, reported.1
Do not initiate bevacizumab therapy until ≥28 days following major surgery and after surgical incision has fully healed.1
Discontinue bevacizumab ≥28 days prior to elective surgery.1 Appropriate interval between discontinuance of bevacizumab and subsequent elective surgery not established, but consider long half-life of bevacizumab.1 (See Half-life under Pharmacokinetics.) Manufacturer recommends resuming therapy only after surgical incision has fully healed.1
Discontinue bevacizumab permanently if wound dehiscence and wound healing complications requiring medical intervention occur.1 (See Boxed Warning.)
Severe, sometimes fatal, hemorrhagic events (e.g., hemoptysis, GI bleeding, hematemesis, CNS hemorrhage, epistaxis, vaginal bleeding) reported.1 (See Boxed Warning.)
Risk of severe or fatal pulmonary hemorrhage in patients with non-small cell lung cancer.1 Serious or fatal pulmonary hemorrhage reported in 31% of patients with squamous cell histology and in 4% of patients with nonsquamous cell histology.1
Mild hemorrhagic events, most commonly grade 1 epistaxis, also reported.1
Infusion reactions (e.g., hypertension, hypertensive crisis associated with neurologic manifestations, wheezing, oxygen desaturation, grade 3 hypersensitivity, chest pain, headache, rigor, diaphoresis) reported.1
Infuse initial doses slowly, increasing rate of infusion as tolerated.1 (See Rate of Administration under Dosage and Administration.)
Non-GI Fistula Formation
Severe, sometimes fatal, non-GI fistula formation involving tracheo-esophageal, bronchopleural, biliary, vaginal, and bladder sites reported; usually occurs within first 6 months of treatment.1 If non-GI fistula formation involving an internal organ occurs, discontinue bevacizumab permanently.1
Serious, sometimes fatal, arterial thromboembolic events (e.g., cerebral infarction, TIA, MI, angina) reported.1 7 8 16 17 Increased risk in patients with a history of arterial thromboembolism or patients >65 years of age.1 7 Weigh risks against benefits of therapy.17 Discontinue therapy permanently if severe arterial thromboembolic event occurs;1 7 safety of resuming therapy after resolution of an arterial thromboembolic event not studied.1
Grade 3 or 4 venous thromboembolic events (e.g., DVT, intra-abdominal venous thrombosis) reported.1 Increased risk of developing second thromboembolic event reported in patients with metastatic colorectal cancer receiving bevacizumab with chemotherapy despite use of full-dose warfarin therapy following an initial venous thromboembolic event.1
Severe hypertension (grade 3 or 4) reported.1
Monitor BP every 2–3 weeks during therapy.1 If hypertension occurs, initiate appropriate antihypertensive therapy and monitor BP regularly.1 Temporarily discontinue therapy in patients with severe hypertension not controlled with medical management.1 Discontinue therapy permanently if hypertensive crisis or hypertensive encephalopathy occurs.1 If therapy is discontinued because of hypertension, monitor BP at regular intervals thereafter.1
Reversible Posterior Leukoencephalopathy Syndrome (RPLS)
RPLS (a brain-capillary leak syndrome) reported.1 29 30 32 May manifest with headache, seizure, lethargy, confusion, blindness, and other visual and neurologic disturbances; mild to severe hypertension also may occur.1 32 Manifestations occurred from 16 hours to 1 year after initiation of bevacizumab.1 32 Magnetic resonance imaging (MRI) is necessary to confirm diagnosis of RPLS.1 32
Closely monitor and maintain strict control of BP during and following bevacizumab infusion.30 If RPLS develops, discontinue bevacizumab and initiate treatment of hypertension as clinically indicated.1 31 32 Symptoms usually lessen or resolve within days of drug discontinuance, but some patients have experienced ongoing neurologic sequelae.1 32 Risk of reinitiating bevacizumab in patients previously experiencing RPLS not known.1 32
Increased incidence and severity of proteinuria reported.1 Severity ranges from clinically silent to nephrotic syndrome.6 Proteinuria with findings of thrombotic microangiopathy on renal biopsy reported in patients receiving bevacizumab alone or in combination with other antineoplastic agents for various cancers.1 37
Monitor patients for development or worsening of proteinuria with serial urinalysis.1 Further assessment (e.g., 24-hour urine collection) recommended if ≥2+ urine dipstick reading occurs.1 Interrupt bevacizumab therapy for moderate proteinuria (≥2 g per 24 hours); resume therapy when proteinuria is <2 g per 24 hours.1 Safety of continuing therapy in patients with moderate to severe proteinuria not known.1
Discontinue bevacizumab permanently in patients with nephrotic syndrome.1
Ovarian failure reported in premenopausal women receiving bevacizumab in combination with chemotherapy (i.e., modified FOLFOX6)† for adjuvant treatment of colorectal cancer.1 Recovery of ovarian function occurred in 22% of patients following discontinuance of bevacizumab.1 Long-term effects on fertility unknown.1
Inform women of childbearing potential of risk of ovarian failure prior to initiating bevacizumab.1
Neutropenia and Infection
Severe (grade 3 or 4) neutropenia, febrile neutropenia, infection with severe neutropenia (sometimes fatal), and serious infections (e.g., pneumonia, catheter infections, wound infections) reported.1
CHF reported; higher risk in patients also receiving or who had previously received anthracyclines.1
Safety of continuation or resumption of bevacizumab in patients who develop cardiac dysfunction not studied.1
Microangiopathic Hemolytic Anemia
Microangiopathic hemolytic anemia reported in patients with solid tumors receiving bevacizumab and sunitinib†;35 36 cases were reversible within 3 weeks following discontinuance of both drugs without other interventions.35 36 Use of bevacizumab in combination with sunitinib is not recommended.35 36
Permanent loss of vision, endophthalmitis (infectious and sterile), intraocular inflammation, retinal detachment, increased IOP, hemorrhage (including conjunctival, vitreous, or retinal hemorrhage), vitreous floaters, ocular hyperemia, and ocular pain or discomfort reported in patients receiving intravitreal injection† of bevacizumab for treatment of various ocular disorders†.1
No difference in overall survival relative to younger adults observed in patients receiving bevacizumab and chemotherapy for metastatic colorectal cancer.1 However, possible increased risk of asthenia, sepsis, deep thrombophlebitis, hypertension, hypotension, MI, CHF, diarrhea, constipation, anorexia, leukopenia, anemia, dehydration, hypokalemia, hyponatremia, nausea, vomiting, ileus, and fatigue.1
Increased incidence of arterial thromboembolic events in patients >66 years of age receiving bevacizumab with chemotherapy compared with younger adults.1 (See Thromboembolism under Cautions.)
Increased risk of proteinuria in patients ≥65 years of age receiving bevacizumab in combination with paclitaxel and carboplatin, compared with younger adults.1 (See Proteinuria under Cautions.)
Possible increased incidence of dyspepsia, GI hemorrhage, edema, epistaxis, increased cough, and voice alteration compared with younger adults.1
Common Adverse Effects
Epistaxis, headache, hypertension, rhinitis, proteinuria, taste alteration, dry skin, rectal hemorrhage, lacrimation disorder, back pain, exfoliative dermatitis.1
Interactions for Bevacizumab
No effect on carboplatin exposure1
No effect on interferon alfa exposure1
Possible decreased paclitaxel exposure after 4 treatment cycles of bevacizumab in combination with paclitaxel and carboplatin1
Relationship between bevacizumab exposure and clinical outcome not studied.1
Metabolized by reticuloendothelial system.3
Eliminated via reticuloendothelial system.3
Approximately 20 days (range: 11–50 days).1
Store diluted solution at 2–8°C for up to 8 hours.1
For information on systemic interactions resulting from concomitant use, see Interactions.
No incompatibilities with PVC or polyolefin bags.1
Sodium chloride 0.9%
Binds to human vascular endothelial growth factor (VEGF) and prevents interaction of VEGF with its receptors (Flt-1, KDR) on the surface of endothelial cells.1 This may result in inhibition of angiogenesis, thus reducing microvascular growth of tumors and inhibiting metastatic disease progression.1 2 3 5
Advice to Patients
Importance of understanding potential risks associated with therapy, including severe hypertension, wound healing complications, arterial thromboembolic events, and ovarian failure.1
Importance of routine monitoring of BP; advise patients to inform clinician if BP is elevated.1
Importance of immediately informing clinician if unusual bleeding, high fever, rigors, sudden worsening of neurologic function, persistent or severe abdominal pain, severe constipation, or vomiting occurs.1
Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs, as well as any concomitant illnesses.1
Importance of informing patients of other important precautionary information. (See Cautions.)
Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.
Please refer to the ASHP Drug Shortages Resource Center for information on shortages of one or more of these preparations.
For injection, concentrate, for IV infusion
25 mg/mL (100 and 400 mg)
AHFS DI Essentials™. © Copyright 2018, Selected Revisions June 30, 2016. American Society of Health-System Pharmacists, Inc., 4500 East-West Highway, Suite 900, Bethesda, Maryland 20814.
1. Genentech, Inc. Avastin (bevacizumab) prescribing information. South San Francisco, CA; 2011 Dec.
2. Kabbinavar F, Hurwitz HI, Fehrenbacher L et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol. 2003; 21:60-5. http://www.ncbi.nlm.nih.gov/pubmed/12506171?dopt=AbstractPlus
3. Genentech, South San Francisco, CA: Personal communication.
4. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004; 350:2335-42. http://www.ncbi.nlm.nih.gov/pubmed/15175435?dopt=AbstractPlus
5. Presta LG, Chen H, O’Connor SJ et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 1997; 57:4593-9. http://www.ncbi.nlm.nih.gov/pubmed/9377574?dopt=AbstractPlus
6. Zondor SD, Medina PJ. Bevacizumab: An angiogenesis Inhibitor with efficacy in colorectal and other malignancies. Ann Pharmacother. 2004; 38:1258-64. http://www.ncbi.nlm.nih.gov/pubmed/15187215?dopt=AbstractPlus
7. Barron H. Dear healthcare provider regarding adverse arterial thromboembolic events associated with Avastin. South San Francisco, CA: Genentech; 2004 Jul.
8. Food and Drug Administration. Avastin (bevacizumab) injection [August 13, 2004: Genentech]. MedWatch drug labeling changes. Rockville, MD; August 2004. From FDA website. http://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm
9. Colon cancer. From: PDQ. Physician data query (database). Bethesda, MD: National Cancer Institute; 2007 Aug 9.
10. Non-small cell lung cancer. From: PDQ. Physician data query (database). Bethesda, MD: National Cancer Institute; 2007 May 1.
11. Sandler A, Gray R, Perry MC et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small lung cancer. N Engl J Med 2006; 355:2542-50. http://www.ncbi.nlm.nih.gov/pubmed/17167137?dopt=AbstractPlus
12. Yang JC, Haworth L, Sherry RM et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med. 2003; 349:427-34. http://www.ncbi.nlm.nih.gov/pubmed/12890841?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=2275324&blobtype=pdf
13. Rini BI, Halabi S, Rosenberg JE et al. CALGB 90206: A phase III trial of bevacizumab plus interferon-alpha versus interferon-alpha monotherapy in metastatic renal cell carcinoma. Proc ASCO 2008 Genitourinary Cancers Symposium. 2008; Abstract 350.
14. Miller KD, Chap LI, Holmes FA et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol. 2005; 23:792-9. http://www.ncbi.nlm.nih.gov/pubmed/15681523?dopt=AbstractPlus
15. Miller K, Wang M, Gralow J et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007; 357:2666-76. http://www.ncbi.nlm.nih.gov/pubmed/18160686?dopt=AbstractPlus
16. Food and Drug Administration. MedWatch—Safety-related drug labeling changes: Avastin (bevacizumab) [January 2005]. From FDA website. http://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm
17. Barron H. Dear healthcare provider letter regarding increased risk of arterial thromboembolic events associated with the use of Avastin in combination with chemotherapy. South San Francisco, CA: Genentech; 2005 Jan 5.
18. Hurwitz HI, Fehrenbacher L, Hainsworth JD et al. Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol. 2005; 23:3502-8. http://www.ncbi.nlm.nih.gov/pubmed/15908660?dopt=AbstractPlus
19. Kabbinavar FF, Schulz J, McCleod M et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol. 2005; 23:3697-705. http://www.ncbi.nlm.nih.gov/pubmed/15738537?dopt=AbstractPlus
20. Kabbinavar FF, Hambleton J, Mass RD et al. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol. 2005; 23:3706-12. http://www.ncbi.nlm.nih.gov/pubmed/15867200?dopt=AbstractPlus
21. Giantonio BJ, Catalano PJ, Meropol NJ et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol. 2007; 25:1539-44. http://www.ncbi.nlm.nih.gov/pubmed/17442997?dopt=AbstractPlus
22. Chen HX, Mooney M, Boron M et al. Phase II multicenter trial of bevacizumab plus fluorouracil and leucovorin in patients with advanced refractory colorectal cancer: an NCI treatment referral center trial TRC-0301. J Clin Oncol. 2006; 24:3354-60. http://www.ncbi.nlm.nih.gov/pubmed/16849749?dopt=AbstractPlus
23. Picus J, Halabi S, Rini B et al. The use of bevacizumab (B) with docetaxel (D) and estramustine (E) in hormone refractory prostate cancer (HRPC): initial results of CALGB 90006. Proc ASCO. 2003; Abstract No. 1578.
24. Kelly W, protocol chair. Phase III randomized study of docetaxel and prednisone with versus without bevacizumab in patients with hormone-refractory metastatic adenocarcinoma of the prostate. Protocol ID: CALGB-90401. Last modified: 7/22/2006. National Cancer Institute: Clinical Trials (database).
25. Kindler H, protocol chair. Phase III randomized study of gemcitabine with versus without bevacizumab in patients with locally advanced or metastatic adenocarcinoma of the pancreas. Protocol ID: CALGB-80303. Last modified: 4/19/2006. National Cancer Institute: Clinical Trials (database).
26. Burger R, Fleming G, protocol chairs. Phase III randomized study of carboplatin and paclitaxel versus carboplatin, paclitaxel, and concurrent bevacizumab with versus without extended bevacizumab in patients with stage III or IV ovarian epithelial or primary peritoneal cancer. Protocol ID: GOG-0218. Last modified: 10/10/2008. National Cancer Institute: Clinical Trials (database).
27. National Comprehensive Cancer Network (NCCN). Clinical practice guidelines in oncology: non-small cell lung cancer. Version 2.2006.
28. Allegra C, protocol chair. Phase III randomized study of adjuvant chemotherapy comprising fluorouracil, leucovorin calcium, and oxaliplatin with versus without bevacizumab in patients with resected stage II or III adenocarcinoma of the colon. Protocol ID: NSABP-C-08. Last modified: 6/20/2008. National Cancer Institute: Clinical Trials (database).
29. Glusker P, Recht L, Lane B. Reversible posterior leukoencephalopathy syndrome and bevacizumab. N Engl J Med. 2006; 354:980-1. http://www.ncbi.nlm.nih.gov/pubmed/16510760?dopt=AbstractPlus
30. Ozcan C, Wong SJ, Hari P. Reversible posterior leukoencephalopathy syndrome and bevacizumab. N Engl J Med. 2006; 354:981-2.
31. Barron H. Reversible posterior leukoencephalopathy syndrome and bevacizumab. Manufacturer reply. N Engl J Med. 2006; 354:982.
32. Barron H. Dear healthcare provider letter regarding reversible posterior leukoencephalopathy syndrome in patients receiving bevacizumab (Avastin). South San Francisco, CA: Genentech; 2006 Sep.
33. Cruzan S (US Food and Drug Administration). FDA approves new combination therapy for lung cancer. Rockville, MD; 2006 Oct 12. Press release P06-166.
34. Steinbrook R. The price of sight—ranibizumab, bevacizumab, and the treatment of macular degeneration. N Engl J Med. 2006; 355:1409-12. http://www.ncbi.nlm.nih.gov/pubmed/17021315?dopt=AbstractPlus
35. Food and Drug Administration. Safety Alert: Avastin (bevacizumab) [July 14 2008]. From FDA web site http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm064952.htm.
36. Barron H. Dear healthcare provider letter: Important drug warning: microangiopathic hemolytic anemia (MAHA) in patients treated with Avastin (bevacizumab) and sunitinib malate. South San Francisco, CA: Genentech; 2008 Jul.
37. Eremina V, Jefferson JA, Kowalewska J et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med. 2008; 358:1129-36. http://www.ncbi.nlm.nih.gov/pubmed/18337603?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=3030578&blobtype=pdf
38. Saltz LB, Clarke S, Diaz-Rubio E et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol. 2008; 26:2013-9. http://www.ncbi.nlm.nih.gov/pubmed/18421054?dopt=AbstractPlus
39. Miles DW, Chan A, Dirix LY et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol. 2010; 28:3239-47. http://www.ncbi.nlm.nih.gov/pubmed/20498403?dopt=AbstractPlus
40. Escudier B, Pluzanska A, Koralewski P et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet. 2007; 370:2103-11.
41. CATT Research Group, Martin DF, Maguire MG et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011; 364:1897-908. http://www.ncbi.nlm.nih.gov/pubmed/21526923?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=3157322&blobtype=pdf
42. Scappaticci FA, Skillings JR, Holden SN et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst. 2007; 99:1232-9. http://www.ncbi.nlm.nih.gov/pubmed/17686822?dopt=AbstractPlus
43. Reidy DL, Chung KY, Timoney JP et al. Bevacizumab 5 mg/kg can be infused safely over 10 minutes. J Clin Oncol. 2007; 25:2691-5. http://www.ncbi.nlm.nih.gov/pubmed/17602073?dopt=AbstractPlus
44. Genentech. Avastin (bevacizumab) prescribing information. South San Francisco, CA; 2008 Mar.
45. Friedman HS, Prados MD, Wen PY et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009; 27:4733-40. http://www.ncbi.nlm.nih.gov/pubmed/19720927?dopt=AbstractPlus
46. Kreisl TN, Kim L, Moore K et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol. 2009; 27:740-5. http://www.ncbi.nlm.nih.gov/pubmed/19114704?dopt=AbstractPlus
47. Cohen MH, Shen YL, Keegan P et al. FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme. Oncologist. 2009; 14:1131-8. http://www.ncbi.nlm.nih.gov/pubmed/19897538?dopt=AbstractPlus
48. US Food and Drug Administration. FDA briefing document from the oncology drugs advisory committee, March 31, 2009. From FDA website (http://www.fda.gov/ohrms/dockets/ac/09/briefing/2009-4427b1-01-FDA.pdf).
49. Escudier B, Bellmunt J, Négrier S et al. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol. 2010; 28:2144-50. http://www.ncbi.nlm.nih.gov/pubmed/20368553?dopt=AbstractPlus
53. Allegra CJ, Yothers G, O’Connell MJ et al. Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08. J Clin Oncol. 2011; 29:11-6. http://www.ncbi.nlm.nih.gov/pubmed/20940184?dopt=AbstractPlus
58. Food and Drug Administration. FDA drug safety communication: Avastin (bevacizumab): Process for removal of breast cancer indication begun. Rockville, MD; 2010 Dec 16. From FDA website. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm237280.htm
59. Food and Drug Administration. Memorandum to the file BLA 125085 Avastin (bevacizumab): Regulatory decision to withdraw Avastin (bevacizumab) first-line metastatic breast cancer indication. Rockville, MD; 2010 Dec 15. From FDA website. http://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM237171.pdf
60. Woodcock J. Dear breast cancer community letter. Silver Spring, MD: Food and Drug Administration; 2010 Dec 16. From FDA website. http://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM237286.pdf
61. Food and Drug Administration. Avastin (bevacizumab) information. Rockville, MD; 2011 Jun 29. From FDA website. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm193900.htm
62. Adult brain tumors treatment. From: PDQ. Physician data query (database). Bethesda, MD: National Cancer Institute; 2010 July 8.
63. Food and Drug Administration. Orphan designation pursuant to Section 526 of the Federal Food and Cosmetic Act as amended by the Orphan Drug Act. (P.L. 97-414). Rockville, MD; From FDA website. http://www.accessdata.fda.gov/scripts/opdlisting/oopd/index.cfm
64. Genentech. Avastin (bevacizumab) prescribing information. South San Francisco, CA; 2011 Sep.
65. Food and Drug Administration. Proposal to withdraw approval for the breast cancer indication for Avastin: Decision of the Commissioner. Rockville, MD; 2011 Nov 18. From FDA website. http://www.fda.gov/downloads/NewsEvents/Newsroom/UCM280546.pdf
66. Food and Drug Administration. Commissioner’s opening statement from media call. Rockville, MD; accessed 2011 Nov 18. From FDA website. http://www.fda.gov/NewsEvents/Newsroom/ucm280585.htm
67. Food and Drug Administration. Questions and answers: Removing metastatic breast cancer as an indication from Avastin’s product labeling. Rockville, MD; accessed 2011 Nov 18. From FDA website. http://www.fda.gov/NewsEvents/Newsroom/ucm280533.htm
68. Food and Drug Administration. FDA news release: FDA Commissioner announces Avastin decision. Rockville, MD; 2011 Nov 18. From FDA website. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm280536.htm
69. Health Canada. Health Canada directs Hoffmann-La Roche to remove use of Avastin (bevacizumab) for the treatment of metastatic breast cancer from the product label. Ottawa, ON; 2011 Nov 28. From Health Canada website. http://www.hc-sc.gc.ca/ahc-asc/media/advisories-avis/_2011/2011_159-eng.php
70. National Institute for Health and Clinical Excellence. Bevacizumab in combination with a taxane for the first-line treatment of metastatic bresat cancer. NICE technology appraisal guidance 214. London, England. 2011 Feb. From NICE website. http://www.nice.org.uk/nicemedia/live/13342/53167/53167.pdf
71. Perren TJ, Swart AM, Pfisterer J et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011; 365:2484-96. http://www.ncbi.nlm.nih.gov/pubmed/22204725?dopt=AbstractPlus
72. Burger RA, Brady MF, Bookman MA et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011; 365:2473-83. http://www.ncbi.nlm.nih.gov/pubmed/22204724?dopt=AbstractPlus
73. Robert NJ, Diéras V, Glaspy J et al. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol. 2011; 29:1252-60. http://www.ncbi.nlm.nih.gov/pubmed/21383283?dopt=AbstractPlus
74. Brufsky AM, Hurvitz S, Perez E et al. RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol. 2011; 29:4286-93. http://www.ncbi.nlm.nih.gov/pubmed/21990397?dopt=AbstractPlus
75. A study of rhuMAb VEGF (bevacizumab) in combination with chemotherapy in patients with previously treated breast cancer. From ClinicalTrials.gov registry. Accessed 2012 Feb 15. http://clinicaltrials.gov/ct2/show/NCT00109239?term=avf2119g&rank=2
76. Gray R, Bhattacharya S, Bowden C et al. Independent review of E2100: a phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer. J Clin Oncol. 2009; 27:4966-72. http://www.ncbi.nlm.nih.gov/pubmed/19720913?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=2799052&blobtype=pdf
77. AHFS Final Determination: Bevacizumab in combination with paclitaxel for the first-line treatment of metastatic breast cancer. Published August 2012.
78. AHFS Final Determination: Bevacizumab in combination with chemotherapy for the treatment of metastatic breast cancer previously treated with cytotoxic chemotherapy. Published August 2012.
80. Mitchell P, Wong TY, Diabetic Macular Edema Treatment Guideline Working Group. Management paradigms for diabetic macular edema. Am J Ophthalmol. 2014; 157:505-13.e1-8. http://www.ncbi.nlm.nih.gov/pubmed/24269850?dopt=AbstractPlus
81. Rajendram R, Fraser-Bell S, Kaines A et al. A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-month data: report 3. Arch Ophthalmol. 2012; 130:972-9. http://www.ncbi.nlm.nih.gov/pubmed/22491395?dopt=AbstractPlus
82. American Academy of Ophthalmology Retina/Vitreous Panel. Preferred practice pattern guidelines: diabetic retinopathy. San Francisco, CA. 2016 Jan. From American Academy of Ophthalmology website. http://www.aao.org/preferred-practice-pattern/diabetic-retinopathy-ppp-updated-2016
83. Diabetic Retinopathy Clinical Research Network, Wells JA, Glassman AR et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med. 2015; 372:1193-203. http://www.ncbi.nlm.nih.gov/pubmed/25692915?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=4422053&blobtype=pdf
84. Wells JA, Glassman AR, Ayala AR et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: two-year results from a comparative effectiveness randomized clinical trial. Ophthalmology. 2016; :1-9. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=4698917&blobtype=pdf
85. Tufail A, Patel PJ, Egan C et al. Bevacizumab for neovascular age related macular degeneration (ABC Trial): multicentre randomised double masked study. BMJ. 2010; 340:c2459. http://www.ncbi.nlm.nih.gov/pubmed/20538634?dopt=AbstractPlus
86. IVAN Study Investigators, Chakravarthy U, Harding SP et al. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology. 2012; 119:1399-411. http://www.ncbi.nlm.nih.gov/pubmed/22578446?dopt=AbstractPlus
87. Chakravarthy U, Harding SP, Rogers CA et al. Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. Lancet. 2013; 382:1258-67. http://www.ncbi.nlm.nih.gov/pubmed/23870813?dopt=AbstractPlus
88. Moja L, Lucenteforte E, Kwag KH et al. Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration. Cochrane Database Syst Rev. 2014; 9:CD011230. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=4262120&blobtype=pdf
89. Chakravarthy U, Harding SP, Rogers CA et al. A randomised controlled trial to assess the clinical effectiveness and cost-effectiveness of alternative treatments to Inhibit VEGF in Age-related choroidal Neovascularisation (IVAN). Health Technol Assess. 2015; 19:1-298. http://www.ncbi.nlm.nih.gov/pubmed/26445075?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=4781416&blobtype=pdf
d. Johnson DH, Fehrenbacher L, Novotny WF et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non–small-cell lung cancer. J Clin Oncol. 2004; 22:2184-91. http://www.ncbi.nlm.nih.gov/pubmed/15169807?dopt=AbstractPlus
e. Genentech. Avastin dosing and administration in the first-line treatment of NSCLC. From Genentech website. Accessed 2007 Feb 7. http://www.avastin.com
f. Genentech. Pivotal NSCLC trial overview. From Genentech website. Accessed 2007 Feb 7. http://www.avastin.com
More about bevacizumab
- Bevacizumab Side Effects
- During Pregnancy or Breastfeeding
- Dosage Information
- Drug Interactions
- Support Group
- En Español
- 24 Reviews
- Drug class: VEGF/VEGFR inhibitors